VivoSeq
Other

Gastric Ulcer

33

Pipeline Programs↗

0

Active Trials↗

15

Companies Involved↗

Gastric Ulcer is a moderately active landscape with 33 programs across 15 companies. The most active players are Hanmi Pharmaceutical Company Limited, Takeda, Otsuka. 8 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

38/100

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited

4 programs

Phase 3Takeda logo

Takeda

3 programs

Phase 3Otsuka logo

Otsuka

2 programs

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3O

Onconic Therapeutics Inc.

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

23

clinical trials

Completed21 · 91%
Unknown status1 · 4%
Terminated1 · 4%

Clinical Trials

Trial Activity

23 trials

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
Completed·PPOZEN·Phase 3·NCT00961350·530 enrolled
Healing Effects of Autologous Platelet Rich Plasma on Gastric Ulcer Caused by Endoscopic Submucosal Dissection
Completed·KKeimyung University Dongsan Medical Center·Phase 3·NCT03220334·20 enrolled
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
Completed·Takeda logoTakeda·Phase 3·NCT03050307·234 enrolled
Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy
Completed·KKorea Otsuka International Asia Arab·Phase 4·NCT00272467·132 enrolled
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
Completed·HHK inno.N Corporation·Phase 3·NCT02761512·306 enrolled
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00633672·400 enrolled
Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?
Completed·KKangdong Sacred Heart Hospital·N/A·NCT01167101·290 enrolled
Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00401752·397 enrolled
Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers
Completed·PPOZEN·Phase 3·NCT00995410·380 enrolled
Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Completed·Otsuka logoOtsuka·Phase 4·NCT00233389·301 enrolled
A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium
Completed·Eisai logoEisai·Phase 4·NCT00125736·520 enrolled
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Completed·PPOZEN·Phase 3·NCT01129011·420 enrolled
Prevention of Gastric Ulcers
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00629512·504 enrolled
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
Completed·PPOZEN·Phase 3·NCT00367211·400 enrolled
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
Completed·Takeda logoTakeda·Phase 3·NCT01452711·482 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)